Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering Cancer Center
New York City
Dr. Michael Mauro received his medical degree from Dartmouth Medical School and completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. He is professor of medicine and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Mauro has practiced as a board-certified hematologist for the past 15 years. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years. There he directed the chronic myeloid leukemia (CML) clinical trial program and was involved in the early development and sentinel clinical studies of targeted therapy for CML.
Dr. Mauro’s clinical expertise is in treating patients with CML as well as other myeloproliferative disorders including myelofibrosis, polycythemia, and thrombocytosis, as well as less common conditions such as eosinophilic and mast cell disorders. His research interests include optimizing therapy response in CML, late and emerging side effects of kinase inhibitors, and decision-making amongst therapies for CML and other myeloproliferative neoplasms. Dr. Mauro’s patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with his patients and their referring providers to personalize recommendations and monitoring given the chronic nature of the disorders he treats.